SCHOLAR ROCK HOLDING CORPORATION Capital Expenditures Incurred but Not yet Paid
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Capital Expenditures Incurred but Not yet Paid of $22.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-11-14
- SCHOLAR ROCK HOLDING CORPORATION capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $13.00K.
- SCHOLAR ROCK HOLDING CORPORATION capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $413.00K, a 12.68% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION capital expenditures incurred but not yet paid for the quarter ending 2021-12-31 was $202.00K, a 78.60% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION capital expenditures incurred but not yet paid for the quarter ending 2021-09-30 was -$625.00K, a 249.88% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION capital expenditures incurred but not yet paid for fiscal 2021 was $212.00K, a 84.50% decline from fiscal 2020.
- SCHOLAR ROCK HOLDING CORPORATION capital expenditures incurred but not yet paid for fiscal 2020 was $1.37M.
- SCHOLAR ROCK HOLDING CORPORATION capital expenditures incurred but not yet paid for fiscal 2018 was $439.00K, a 176.10% increase from fiscal 2017.
- SCHOLAR ROCK HOLDING CORPORATION capital expenditures incurred but not yet paid for fiscal 2017 was $159.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2024-09-30 | $22.00K 10-Q · filed 2025-11-14 | |||
| 2024-03-31 | $13.00K 10-Q · filed 2025-05-14 | |||
| 2022-09-30 | $112.00K 10-Q · filed 2023-11-07 | |||
| 2022-03-31 | $413.00K 10-Q · filed 2023-05-09 | $615.00K derived: sum of 2 quarters · filed 2023-05-09 | -$10.00K derived: sum of 3 quarters · filed 2023-05-09 | $152.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$423.00K derived: sum of 2 quarters · filed 2023-03-07 | -$261.00K derived: sum of 3 quarters · filed 2023-03-07 | $212.00K 10-K · filed 2023-03-07 |
| 2021-09-30 | -$625.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$463.00K derived: sum of 2 quarters · filed 2022-11-14 | $10.00K 10-Q · filed 2022-11-14 | $954.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $162.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $635.00K 10-Q · filed 2022-08-08 | $1.58M derived: sum of 3 quarters · filed 2022-08-08 | $2.00M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $473.00K 10-Q · filed 2022-05-16 | $1.42M derived: sum of 2 quarters · filed 2022-05-16 | $1.83M derived: sum of 3 quarters · filed 2022-05-16 | $1.83M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $944.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $1.36M derived: sum of 2 quarters · filed 2022-03-07 | $1.36M derived: sum of 3 quarters · filed 2022-03-07 | $1.37M 10-K · filed 2022-03-07 |
| 2020-09-30 | $417.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $414.00K derived: sum of 2 quarters · filed 2021-11-09 | $424.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $7.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $10.00K 10-Q · filed 2021-05-13 | |||
| 2019-09-30 | $805.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $349.00K derived: sum of 2 quarters · filed 2020-11-09 | $832.00K 10-Q · filed 2020-11-09 | $1.09M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$456.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $27.00K 10-Q · filed 2020-08-07 | $289.00K derived: sum of 3 quarters · filed 2020-08-07 | |
| 2019-03-31 | $483.00K 10-Q · filed 2020-05-07 | $745.00K derived: sum of 2 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $262.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $439.00K 10-K · filed 2020-03-12 | ||
| 2018-09-30 | $177.00K 10-Q · filed 2019-11-12 | |||
| 2018-03-31 | $13.00K 10-Q · filed 2019-05-15 | $113.00K derived: sum of 2 quarters · filed 2019-05-15 | ||
| 2017-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $159.00K 10-K · filed 2019-03-19 | ||
| 2017-09-30 | $59.00K 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |